Literature DB >> 21652726

Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice.

Alexander G Robling1, Rajendra Kedlaya, Shana N Ellis, Paul J Childress, Joseph P Bidwell, Teresita Bellido, Charles H Turner.   

Abstract

PTH is a potent calcium-regulating factor that has skeletal anabolic effects when administered intermittently or catabolic effects when maintained at consistently high levels. Bone cells express PTH receptors, but the cellular responses to PTH in bone are incompletely understood. Wnt signaling has recently been implicated in the osteo-anabolic response to the hormone. Specifically, the Sost gene, a major antagonist of Wnt signaling, is down-regulated by PTH exposure. We investigated this mechanism by treating Sost-deficient mice and their wild-type littermates with anabolic and catabolic regimens of PTH and measuring the skeletal responses. Male Sost(+/+) and Sost(-/-) mice were injected daily with human PTH 1-34 (0, 30, or 90 μg/kg) for 6 wk. Female Sost(+/+) and Sost(-/-) mice were continuously infused with vehicle or high-dose PTH (40 μg/kg · d) for 3 wk. Dual energy x-ray absorptiometry-derived measures of intermittent PTH (iPTH)-induced bone gain were impaired in Sost(-/-) mice. Further probing revealed normal or enhanced iPTH-induced cortical bone formation rates but concomitant increases in cortical porosity among Sost(-/-) mice. Distal femur trabecular bone was highly responsive to iPTH in Sost(-/-) mice. Continuous PTH (cPTH) infusion resulted in equal bone loss in Sost(+/+) and Sost(-/-) mice as measured by dual energy x-ray absorptiometry. However, distal femur trabecular bone, but not lumbar spine trabecular bone, was spared the bone-wasting effects of cPTH in Sost(-/-) mice. These results suggest that changes in Sost expression are not required for iPTH-induced anabolism. iPTH-induced resorption of cortical bone might be overstimulated in Sost-deficient environments. Furthermore, Sost deletion protects some trabecular compartments, but not cortical compartments, from bone loss induced by high-dose PTH infusion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21652726      PMCID: PMC3138236          DOI: 10.1210/en.2011-0049

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  52 in total

1.  An LDL-receptor-related protein mediates Wnt signalling in mice.

Authors:  K I Pinson; J Brennan; S Monkley; B J Avery; W C Skarnes
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

2.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

Authors:  David G Winkler; May Kung Sutherland; James C Geoghegan; Changpu Yu; Trenton Hayes; John E Skonier; Diana Shpektor; Mechtild Jonas; Brian R Kovacevich; Karen Staehling-Hampton; Mark Appleby; Mary E Brunkow; John A Latham
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

3.  Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment.

Authors:  P J Niziolek; S Murthy; S N Ellis; K B Sukhija; T A Hornberger; C H Turner; A G Robling
Journal:  J Cell Physiol       Date:  2009-12       Impact factor: 6.384

4.  Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos.

Authors:  Burak Demiralp; Hen-Li Chen; Amy J Koh; Evan T Keller; Laurie K McCauley
Journal:  Endocrinology       Date:  2002-10       Impact factor: 4.736

5.  A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.

Authors:  Jean-Jacques Body; Gregory A Gaich; Wim H Scheele; Pandurang M Kulkarni; Paul D Miller; Anne Peretz; Robin K Dore; Ricardo Correa-Rotter; Alexandra Papaioannou; David C Cumming; Anthony B Hodsman
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

6.  Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Authors:  Bruce Ettinger; Javier San Martin; Gerald Crans; Imre Pavo
Journal:  J Bone Miner Res       Date:  2004-01-19       Impact factor: 6.741

7.  Sclerostin binds and regulates the activity of cysteine-rich protein 61.

Authors:  Theodore A Craig; Resham Bhattacharya; Debabrata Mukhopadhyay; Rajiv Kumar
Journal:  Biochem Biophys Res Commun       Date:  2009-12-31       Impact factor: 3.575

8.  Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Authors:  Teresita Bellido; A Afshan Ali; Lilian I Plotkin; Qiang Fu; Igor Gubrij; Paula K Roberson; Robert S Weinstein; Charles A O'Brien; Stavros C Manolagas; Robert L Jilka
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

9.  Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.

Authors:  Hong Y Choi; Marco Dieckmann; Joachim Herz; Andreas Niemeier
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

10.  Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone.

Authors:  Shibing Yu; Renny T Franceschi; Min Luo; Jie Fan; Di Jiang; Huiling Cao; Tae-Geon Kwon; Yumei Lai; Jian Zhang; Kenneth Patrene; Kurt Hankenson; G David Roodman; Guozhi Xiao
Journal:  PLoS One       Date:  2009-10-23       Impact factor: 3.240

View more
  31 in total

Review 1.  Signaling pathways affecting skeletal health.

Authors:  Pierre J Marie
Journal:  Curr Osteoporos Rep       Date:  2012-09       Impact factor: 5.096

Review 2.  The Key Role of the Blood Supply to Bone.

Authors:  Massimo Marenzana; Timothy R Arnett
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

3.  The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice.

Authors:  Yingben Xue; Yongjun Xiao; Jingning Liu; Andrew C Karaplis; Martin R Pollak; Edward M Brown; Dengshun Miao; David Goltzman
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-01-24       Impact factor: 4.310

Review 4.  Role and mechanism of action of sclerostin in bone.

Authors:  Jesus Delgado-Calle; Amy Y Sato; Teresita Bellido
Journal:  Bone       Date:  2016-10-12       Impact factor: 4.398

5.  Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.

Authors:  Fatma Gossiel; Jessica R Scott; Margaret A Paggiosi; Kim E Naylor; Eugene V McCloskey; Nicola F A Peel; Jennifer S Walsh; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

6.  The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b.

Authors:  Jau-Yi Li; Lindsey D Walker; Abdul Malik Tyagi; Jonathan Adams; M Neale Weitzmann; Roberto Pacifici
Journal:  J Bone Miner Res       Date:  2014-01       Impact factor: 6.741

7.  Postnatal deletion of β-catenin in osterix-expressing cells is necessary for bone growth and intermittent PTH-induced bone gain.

Authors:  Caixia Yu; Miao Xuan; Mingzhu Zhang; Qianqian Yao; Keqin Zhang; Xiuzhen Zhang; Jun Guo; Lige Song
Journal:  J Bone Miner Metab       Date:  2017-11-09       Impact factor: 2.626

8.  Role of paraoxonase-1 in bone anabolic effects of parathyroid hormone in hyperlipidemic mice.

Authors:  Jinxiu Lu; Henry Cheng; Elisa Atti; Diana M Shih; Linda L Demer; Yin Tintut
Journal:  Biochem Biophys Res Commun       Date:  2013-01-03       Impact factor: 3.575

Review 9.  WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Authors:  Roland Baron; Michaela Kneissel
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

10.  N-cadherin restrains PTH activation of Lrp6/β-catenin signaling and osteoanabolic action.

Authors:  Leila Revollo; Jacqueline Kading; Sung Yeop Jeong; Jiemin Li; Valerie Salazar; Gabriel Mbalaviele; Roberto Civitelli
Journal:  J Bone Miner Res       Date:  2015-02       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.